This grant funds the validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, treatment response, and prevention, supporting both analytical and clinical validation phases.
This grant funds projects to further develop and validate innovative technologies that advance cancer research or clinical care, focusing on technical improvements and rigorous validation for broad adoption.
The National Cancer Institute funds further development and technical validation of emerging cancer research technologies backed by preliminary feasibility data; clinical trials are not allowed.
This grant funds early-stage, highly innovative technology development projects to improve cancer research or clinical care, focusing on proof-of-concept studies with high potential impact in cancer-related fields.
NCI supports research on how biospecimen collection, processing, and storage affect biomarkers, aiming to standardize handling and improve clinical assay development; clinical trials are not allowed.
NIH will fund investigator-initiated multi-site or decentralized clinical trials relevant to its mission, supporting planning and implementation over up to 7 years using a milestone-driven UG3/UH3 grant mechanism.